NVO vs GSK

Head-to-Head Stock Analysis & Investment Rating

Last Updated: May 21, 2026

NVO

63.3
AI Score
VS
NVO Wins

GSK

62.0
AI Score

Investment Advisor Scores

NVO

May 21, 2026
63score
Recommendation
BUY

GSK

May 21, 2026
62score
Recommendation
BUY

AI Analyst Insights

Detailed Metrics Comparison

Metric NVO GSK Winner
Forward P/E 13.1926 9.8135 GSK
PEG Ratio 1.4816 0.4986 GSK
Revenue Growth 24.0% 1.5% NVO
Earnings Growth 67.1% 8.4% NVO
Tradestie Score 63.3/100 62.0/100 NVO
Profit Margin 37.2% 17.8% NVO
Beta 1.00 1.00 Tie
Implied Volatility N/A N/A Tie
AI Recommendation BUY BUY Tie

Frequently Asked Questions

Based on our detailed analysis, NVO is currently the stronger investment candidate, winning 4 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.